by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Email this page to a friend
Search this issue
Index - jump to page or section
Archive - view past issues
Australian Journal of Pharmacy : March 2005
The latest word in simvastatin From the first name in generics Available from 1st April 2005 Alphapharm’s own generic simvastatin is coming. For more information on Zimstat and the A to Z of generics, talk to your Alphapharm Representative. PBS Information: This product is not listed on the PBS. Please review Product Information before prescribing. Full disclosure Product Information is available on request from Alphapharm Pty Limited. ZIMSTAT® (simvastatin): INDICATIONS: ZIMSTAT® is indicated as an adjunct to diet for treatment of hypercholesterolaemia. ZIMSTAT® is indicated in patients at high risk of CHD (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing CHD to reduce: the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalization due to angina pectoris. CONTRAINDICATIONS: Active hepatic disease; unexplained transaminase elevation; myopathy secondary to other lipid lowering agents; pregnancy; lactation. PRECAUTIONS: Monitor eyes, liver; hepatic, renal impairment; high alcohol intake; major medical, surgical (incl elective) condition (interrupt therapy); children. ADVERSE EVENTS: Raised LFTs, CK; rhabdomyolysis; myopathy; peripheral neuropathy; paraesthesia; GI upset; others see full PI. INTERACTIONS: Coumarin anticoagulants; gemfibrozil, other fibrates; nicotinic acid; erythromycin; clarithromycin; nefazodone; cyclosporin; itraconazole; ketoconazole; digoxin; verapamil; amiodarone; HIV protease inhibitors, grapefruit juice; diltiazem; other CYP3A4 inhibitors. DOSAGE: Range 10-80 mg/day as single evening dose, adjust every 4 weeks if necessary. Existing CHD or high risk: initially 40 mg/day. Others: initially 10-20 mg/day. Renal impairment, potential drug interactions: max 10-20 mg/day; See full PI. ZIMSTAT® ABN 93 002 359 739 Chase Building 2, Wentworth Park Road, Glebe NSW 2037, Australia. www.alphapharm.com.au Medical Inforrmation Line 1800 028 365. EVO9120/AJP is a registered trademark of Alphapharm Pty Limited,